Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Subscribe To Our Newsletter & Stay Updated